Thyroid (boxed warning)
The thyroid boxed warning is the prominent black-box warning on semaglutide and tirzepatide labels about a risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It’s the scariest-sounding thing on the label, so it deserves a clear, honest read.
Where it comes from
In rodent studies, these drugs caused thyroid C-cell tumors in rats and mice. That finding triggered the boxed warning as a precaution. The crucial uncertainty: it’s not known whether this translates to humans. Rodent thyroid C-cells are considerably more sensitive to GLP-1 stimulation than human ones, and human data so far has not established a causal link to MTC. The warning reflects appropriate caution given an animal signal, not a demonstrated human cancer risk.
Who should not take these drugs
The warning translates into firm contraindications. You should not take semaglutide or tirzepatide if you or your family have a history of:
- Medullary thyroid carcinoma (MTC), or
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — a genetic condition.
This is a standard screening question before starting, and an honest answer matters.
How to hold it in perspective
For someone without that personal or family history, the medical consensus has been that the benefits outweigh this theoretical, rodent-derived risk — which is why these drugs are widely prescribed despite the boxed warning. Report symptoms like a neck lump, trouble swallowing, or persistent hoarseness to your doctor, and make sure your prescriber has your family thyroid history. As with everything here: the label is information for a conversation with your clinician, not a verdict to reach alone.